A novel platform for attenuating immune hyperactivity using EXO‐CD24 in COVID‐19 and beyond

A small but significant proportion of COVID‐19 patients develop life‐threatening cytokine storm. We have developed a new anti‐inflammatory drug, EXO‐CD24, a combination of an immune checkpoint (CD24) and a delivery platform (exosomes). CD24 inhibits the NF‐kB pathway and the production of cytokines/...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapira, Shiran, Ben Shimon, Marina, Hay‐Levi, Mori, Shenberg, Gil, Choshen, Guy, Bannon, Lian, Tepper, Michael, Kazanov, Dina, Seni, Jonathan, Lev‐Ari, Shahar, Peer, Michael, Boubas, Dimitrios, Stebbing, Justin, Tsiodras, Sotirios, Arber, Nadir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349550/
https://www.ncbi.nlm.nih.gov/pubmed/35776000
http://dx.doi.org/10.15252/emmm.202215997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349550/
https://www.ncbi.nlm.nih.gov/pubmed/35776000
http://dx.doi.org/10.15252/emmm.202215997

Ejemplares similares